Assertio Therapeutics Stock News

Assertio Holdings, Inc. (NASDAQ:ASRT ) Q1 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Matthew Kreps - Darrow Associates, IR Heather Mason - Interim CEO Ajay Patel - CFO P

LAKE FOREST, Ill., April 25, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities

LAKE FOREST, Ill., April 01, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities

LAKE FOREST, Ill., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company that acquires, commercializes and

Assertio (ASRT) appears weighed down by the recent leadership transition. The company is also facing challenges with sales of its product franchisee of late.

Assertio Holdings has dropped substantially and is down more than 70% in the past year. Assertio Holdings appears to have been oversold based on quantitative factors. It trades at a very low enterpris

Assertio (ASRT) appoints Heather Mason as its interim CEO as its current CEO, Dan Peisert, steps down from his role. Shares of the company fall on the same.

Today's backdrop of a predicted fall in interest rates, as well as the expectation that indices like the S&P 500 will surge higher, has some important considerations for penny stocks. Penny stocks ten

Assertio Holdings Inc. (NASDAQ:ASRT ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Matt Kreps - Darrow Associates, IR Dan Peisert - President and CEO Ajay Patel -

LAKE FOREST, Ill., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products t

Assertio Holdings has undergone a significant transformation in its business model, reducing debt and exiting the opioid business. The company's recent performance has shown strong growth, with increa

Investors need to pay close attention to Assertio (ASRT) stock based on the movements in the options market lately.

Investors need to pay close attention to Assertio (ASRT) stock based on the movements in the options market lately.

Assertio (NASDAQ: ASRT ) stock is falling hard on Friday after the pharmaceutical company released its Q2 earnings report. Assertio disappointed investors with its adjusted earnings per share of 19 c

The stock is down 33% from its 52-week high. Q2 revenue estimates are low. Lead product's use may be expanding.